Partner 16: Genedata AG, Basel, Switzerland
Genedata employs in house developed and commercially available software (e.g., Genedata Expressionist®, Genedata Phylosopher®, Genedata Screener®) to analyze high-volume, complex data in (epi-)genomics, transcriptomics, proteomics, metabolomics, and compound screening. In numerous collaborations with academia and the pharmaceutical industry. Genedata has proven its extensive experience in the comprehensive and integrated analysis and interpretation of large and complex data sets. Genedata has been partner of several EU funded consortia focussing on biomarker research, systems biology, and toxicogenomics, respectively, for example EuRhythDia, diXa, and ModENP-Tox (all FP7), carcinoGENOMCS, InnoMed PredTox, NewGeneris, Proligen, and INCA (FP6). EuRhythDia is a project studying the potential for chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population.
Partner 16 team leader:
Dr Timo Wittenberger
Genedata’s contribution to the HUMAN project will focus on the integrated analysis of the different data sets generated within the project and defined in WP9. Data processing pipelines will be established for standardised QC, pre-processing, and normalisation of ‘omics data. An integrated, multivariate analysis of all ‘omics data types will be performed to establish statistically significant associations with disease factors and clinical parameters. Functional relevance of such associations will be determined by elucidation of cross-platform evidence for regulatory and metabolic networks affected in a given model. Meta-analysis of data from various disease models will be performed, to determine common and differentiating mechanisms, respectively. New probabilistic methods will be developed specifically to address the challenges of analysing data from a humanised in mouse models, e.g. to discriminate NGS reads originating from human vs. mouse cells.
1. Yildirimman R et al. (2011) Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. Dec; 124(2):278-90.
2. Boitier E et al. (2011) A comparative integrated transcript analysis and functional characterisation of differential mechanisms for induction of liver hypertrophy in the rat. Toxicol Appl Pharmacol. Apr 15;252(2):85-96.
3. Matheis KA et al. (2011) Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. Toxicol Appl Pharmacol. Apr 15;252(2):112-22.
4. Suter L et al. (2011) EU framework 6 project: predictive toxicology (PredTox)–overview and outcome. Toxicol Appl Pharmacol. Apr 15;252(2):73-84.
5. Moretti S et al. (2008) Combining Shapley value and statistics to the analysis of gene expression data in children exposed to air pollution. BMC Bioinformatics Sep 2;9:361.
6. Vinken M et al. (2008) The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutat Res. Sep-Oct;659(3):202-10.
7. Lewin J et al. (2007) Comparative DNA methylation analysis in normal and tumour tissues and in cancer cell lines using differential methylation hybridisation. Int J Biochem Cell Biol. 39(7-8):1539-50.